Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 240 participants.

Also called NCT06429384

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 240 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06429384
Other papers using this trial's data
  • Loberamisal injection for the treatment of acute ischaemic stroke: a multicentre, randomised, double-blind, placebo-controlled phase II clinical trial Stroke and vascular neurology, 2026-08-27 DOI, PubMed 41218852, PMC13540287 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06429384. Randomized; quadruple masking; primary purpose treatment. Start 2023-06-04 (actual); primary completion 2023-11-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Y-3 Injection in the Treatment of Acute Ischemic Stroke Phase II Clinical Trial
Condition
Acute Ischemic Stroke
Intervention (Drug)
Y-3 Injection/Y-3 blank injection
Lead sponsor
Beijing Tiantan Hospital (class: other)
Collaborator
Neurodawn Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06429384
Content hash
3fbc843554807e6c729788b6200742374b2242f2de462046d664f2db91e143e4